Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa
Condition: Epidermolysis Bullosa Dystrophica, Recessive Intervention: Biological: mesenchymal stem cells derived from bone marrow (BM-MSCs) Sponsors: Instituto de Investigación Hospital Universitario La Paz; Universidad Carlos III Madrid (TERMeG); St John’s Institute of Dermatology Kings College London; Instituto de Salud Carlos III; DEBRA; CIBER Enfermedades raras Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Dermatology | Epidermolysis Bullosa | Hospitals | Research | Skin | Stem Cell Therapy | Stem Cells | Study